CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer

被引：0

作者：

Matsubara, N. ^{[1
]}

Agarwal, N. ^{[2
]}

Smith, M. R. ^{[3
]}

Mckay, R. R. ^{[4
]}

Todenhofer, T. ^{[5
]}

Piulats Rodriguez, J. M. ^{[6
]}

Chung, K. L. ^{[7
]}

Heirich, D. ^{[8
]}

Sherwood, S. ^{[9
]}

Schaverien, C. ^{[10
]}

Fasnacht, N. ^{[11
]}

Lithio, A. ^{[12
]}

Nacerddine, K. ^{[13
]}

Zhang, T. ^{[14
]}

机构：

[1] Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, Japan

[2] Univ Utah Hlth, Huntsman Canc Inst, Oncol Internal Med Dept, Salt Lake City, UT USA

[3] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Oncol, Boston, MA USA

[4] Univ Calif San Diego UCSD, Med, La Jolla, CA USA

[5] Studienpraxis Urol, Clin Trial Unit, Nuertingen, Germany

[6] Hosp Duran & Reynals, ICO Inst Catala Oncol Hosp, Dept Med Oncol, Barcelona, Spain

[7] Eli Lilly & Co, Oncol, New York, NY USA

[8] Loxo Oncol Inc, Clin Sci, South San Francisco, CA USA

[9] Eli Lilly & Co, Med, West Ryde, NSW, Australia

[10] Eli Lilly & Co, Oncol, Indianapolis, IN USA

[11] Eli Lilly Suisse SA, Oncol Dept, Vernie, Switzerland

[12] Eli Lilly & Co, Stat Dept, Indianapolis, IN USA

[13] Eli Lilly France, Global Clin Dev, Neuilly sur Seine, France

[14] UT Southwestern Med Ctr, Simmons Comprehens Canc Ctr, Internal Med Dept, Dallas, TX USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.791

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

284TiP

引用

页码：S1582 / S1583

页数：2

共 50 条

[31] A phase 3 randomized, placebo-controlled double-blind study of ARN-509 plus abiraterone acetate (AA) in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).
Rathkopf, Dana E.
Attard, Gerhardt
Efstathiou, Eleni
Yu, Margaret K.
Griffin, Thomas W.
Todd, Mary Beth
Wu, Daphne
Kheoh, Thian
Zhao, Xin
Saad, Fred
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[32] Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
Rugo, Hope S.
Stopeck, Alison T.
Joy, Anil A.
Chan, Stephen
Verma, Shailendra
Lluch, Anna
Liau, Katherine F.
Kim, Sinil
Bycott, Paul
Rosbrook, Brad
Bair, Angel H.
Soulieres, Denis
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2459 - 2465
[33] Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).
Chehrazi-Raffle, Alex
Morgans, Alicia K.
Gschwend, Jurgen E.
Shore, Neal D.
Ross, Ashley
Feng, Felix Y.
Hope, Thomas A.
Trandafir, Lucia
Kuss, Iris
Le Berre, Marie-Aude
Joensuu, Heikki
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS254 - TPS254
[34] Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).
Morgans, Alicia K.
Niazi, Tamim
Shore, Neal D.
Gschwend, Juergen E.
Ross, Ashley
Hope, Thomas A.
Chehrazi-Raffle, Alex
Supiot, Stephane
Barthelemy, Philippe
Roder, Andreas
Gomes, Andrea Juliana
Imbroda, Bernardo Herrera
Gratton, Matthieu
Ruiz, Carmen Belen Congregado
Joensuu, Heikki
Dimova-Dobreva, Miryana
Le Berre, Marie-Aude
Kuss, Iris
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS432 - TPS432
[35] First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC) Randomized, double-blind Phase III Study of Pembrolizumab (MK-3475) plus Enzalutamide plus ADT compared with Placebo Plus Enzalutamide Plus ADT in Participants with metastatic hormone-sensitive Prostate Cancer (mHSPC) (KEYNOTE-991) - AP 108/19 of the AUO
Rexer, H.
Retz, M.
Hammerer, P.
UROLOGE, 2021, 60 (07): : 987 - 988
[36] Final Results From ACIS, a Randomized, Placebo-Controlled Double-Blind Phase 3 Study of Apalutamide and Abiraterone Acetate Plus Prednisone (AAP) Versus AAP in Patients With Chemo-Naive Metastatic Castration-Resistant Prostate Cancer
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 5 - 6
[37] A randomized phase II study of ADT plus abiraterone versus ADT plus abiraterone plus docetaxel in patients with low-volume metastatic hormone-sensitive prostate cancer
Fenton, Sarah Elizabeth
Kocherginsky, Masha
VanderWeele, David James
Hussain, Maha H. A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[38] BENEFIT OF ABIRATERONE ACETATE PLUS PREDNISONE (AA plus P) ADDED TO ANDROGEN DEPRIVATION THERAPY (ADT) IN PATIENTS WITH HIGH-RISK, NEWLY DIAGNOSED METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Metin, H.
McQuarrie, K.
Thilakarathne, M.
Diels, J.
Ito, T.
Li, T.
Sulur, G.
Chi, K. N.
Fizazi, K.
VALUE IN HEALTH, 2018, 21 : S38 - S38
[39] Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients
Takashi Ueda
Kazutoshi Fujita
Mitsuhisa Nishimoto
Takumi Shiraishi
Masatsugu Miyashita
Naruhiro Kayukawa
Yuichi Nakamura
Satoshi Sako
Ryota Ogura
Atsuko Fujihara
Takafumi Minami
Fumiya Hongo
Koji Okihara
Kazuhiro Yoshimura
Hirotsugu Uemura
Osamu Ukimura
World Journal of Urology, 2022, 40 : 2939 - 2946
[40] Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients
Ueda, Takashi
Fujita, Kazutoshi
Nishimoto, Mitsuhisa
Shiraishi, Takumi
Miyashita, Masatsugu
Kayukawa, Naruhiro
Nakamura, Yuichi
Sako, Satoshi
Ogura, Ryota
Fujihara, Atsuko
Minami, Takafumi
Hongo, Fumiya
Okihara, Koji
Yoshimura, Kazuhiro
Uemura, Hirotsugu
Ukimura, Osamu
WORLD JOURNAL OF UROLOGY, 2022, 40 (12) : 2939 - 2946

← 1 2 3 4 5 →